BR112016002401A8 - Métodos para reduzir as taxas de exacerbação de asma usando benralizumab - Google Patents
Métodos para reduzir as taxas de exacerbação de asma usando benralizumabInfo
- Publication number
- BR112016002401A8 BR112016002401A8 BR112016002401A BR112016002401A BR112016002401A8 BR 112016002401 A8 BR112016002401 A8 BR 112016002401A8 BR 112016002401 A BR112016002401 A BR 112016002401A BR 112016002401 A BR112016002401 A BR 112016002401A BR 112016002401 A8 BR112016002401 A8 BR 112016002401A8
- Authority
- BR
- Brazil
- Prior art keywords
- benralizumab
- methods
- reducing
- asthma
- asthma exacerbation
- Prior art date
Links
- 229950000321 benralizumab Drugs 0.000 title abstract 4
- 208000037874 Asthma exacerbation Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 208000006673 asthma Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 229940100602 interleukin-5 Drugs 0.000 abstract 1
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Abstract
USO DE BENRALIZUMAB OU DE UM SEU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO PARA REDUZIR AS TAXAS DE EXACERBAÇÃO DE ASMA E BENRALIZUMAB OU DE UM SEU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO PARA USO EM UM MÉTODO PARA REDUÇÃO DA TAXA DE EXACERBAÇÃO ANUAL DE ASMAN. Este documento são conferidos métodos para redução de exacerbações de asma em um paciente com asma, compreendendo a administração ao paciente de uma quantidade eficaz de um anticorpo receptor da anti-interleucina-5 (IL-5R) benralizumab ou de um seu fragmento de ligação ao antígeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361864944P | 2013-08-12 | 2013-08-12 | |
PCT/US2014/050080 WO2015023504A1 (en) | 2013-08-12 | 2014-08-07 | Methods for reducing exacerbation rates of asthma using benralizumab |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016002401A2 BR112016002401A2 (pt) | 2017-09-12 |
BR112016002401A8 true BR112016002401A8 (pt) | 2018-06-12 |
Family
ID=52448837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016002401A BR112016002401A8 (pt) | 2013-08-12 | 2014-08-07 | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab |
Country Status (25)
Country | Link |
---|---|
US (2) | US9441037B2 (pt) |
EP (1) | EP3033101B1 (pt) |
JP (4) | JP6746495B2 (pt) |
KR (2) | KR20220057637A (pt) |
CN (2) | CN111588848A (pt) |
AU (2) | AU2014306956B2 (pt) |
BR (1) | BR112016002401A8 (pt) |
CA (1) | CA2918105C (pt) |
CY (1) | CY1122132T1 (pt) |
DK (1) | DK3033101T3 (pt) |
ES (1) | ES2716906T3 (pt) |
HK (2) | HK1221644A1 (pt) |
HR (1) | HRP20190405T1 (pt) |
HU (1) | HUE042607T2 (pt) |
LT (1) | LT3033101T (pt) |
ME (1) | ME03348B (pt) |
MX (1) | MX368508B (pt) |
PL (1) | PL3033101T3 (pt) |
PT (1) | PT3033101T (pt) |
RS (1) | RS58404B1 (pt) |
RU (1) | RU2676333C2 (pt) |
SG (2) | SG11201600481UA (pt) |
SI (1) | SI3033101T1 (pt) |
TR (1) | TR201903312T4 (pt) |
WO (1) | WO2015023504A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3520811T (pt) * | 2013-08-12 | 2021-03-15 | Astrazeneca Ab | Métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumabe |
RU2020123894A (ru) | 2013-08-12 | 2020-09-18 | Астразенека Аб | Способы нормализации симптомов астмы с применением бенрализумаба |
SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
CN113350278B (zh) * | 2013-10-24 | 2023-03-24 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
US10846696B2 (en) | 2015-08-24 | 2020-11-24 | Samsung Electronics Co., Ltd. | Apparatus and method for trusted execution environment based secure payment transactions |
US10699274B2 (en) | 2015-08-24 | 2020-06-30 | Samsung Electronics Co., Ltd. | Apparatus and method for secure electronic payment |
AU2016349113A1 (en) | 2015-11-04 | 2018-06-07 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
ES2981555T3 (es) | 2017-01-04 | 2024-10-09 | Worg Pharmaceuticals Zhejiang Co Ltd | Péptidos de S-arrestina y usos terapéuticos de los mismos |
RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
TW202021983A (zh) * | 2018-09-21 | 2020-06-16 | 美商安納普提斯生物公司 | 用於嗜伊紅性氣喘之抗il-33療法 |
TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
EP2275541B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7404953B2 (en) | 2000-02-15 | 2008-07-29 | Kyowa Hakko Kogyo Co., Ltd. | Methods using eosinophil-specific apoptosis inducer |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
JPWO2005035583A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Il−5受容体に特異的に結合する抗体組成物 |
US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
BRPI0811526A2 (pt) * | 2007-05-14 | 2017-05-16 | Biowa Inc | uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa |
RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
WO2011062984A1 (en) * | 2009-11-18 | 2011-05-26 | Medicinova, Inc. | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom |
CA2817380C (en) * | 2010-12-16 | 2019-06-04 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
EP2710370A4 (en) * | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
KR20140097217A (ko) | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
PT3520811T (pt) * | 2013-08-12 | 2021-03-15 | Astrazeneca Ab | Métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumabe |
RU2020123894A (ru) | 2013-08-12 | 2020-09-18 | Астразенека Аб | Способы нормализации симптомов астмы с применением бенрализумаба |
-
2014
- 2014-08-07 CN CN202010449434.5A patent/CN111588848A/zh active Pending
- 2014-08-07 AU AU2014306956A patent/AU2014306956B2/en active Active
- 2014-08-07 SG SG11201600481UA patent/SG11201600481UA/en unknown
- 2014-08-07 TR TR2019/03312T patent/TR201903312T4/tr unknown
- 2014-08-07 US US14/453,942 patent/US9441037B2/en active Active
- 2014-08-07 DK DK14835826.0T patent/DK3033101T3/en active
- 2014-08-07 SG SG10202005560UA patent/SG10202005560UA/en unknown
- 2014-08-07 ES ES14835826T patent/ES2716906T3/es active Active
- 2014-08-07 RU RU2016108723A patent/RU2676333C2/ru active
- 2014-08-07 CN CN201480043448.XA patent/CN105451760A/zh active Pending
- 2014-08-07 HU HUE14835826A patent/HUE042607T2/hu unknown
- 2014-08-07 MX MX2016001383A patent/MX368508B/es active IP Right Grant
- 2014-08-07 ME MEP-2019-75A patent/ME03348B/me unknown
- 2014-08-07 KR KR1020227013308A patent/KR20220057637A/ko not_active Application Discontinuation
- 2014-08-07 EP EP14835826.0A patent/EP3033101B1/en active Active
- 2014-08-07 RS RS20190305A patent/RS58404B1/sr unknown
- 2014-08-07 LT LTEP14835826.0T patent/LT3033101T/lt unknown
- 2014-08-07 CA CA2918105A patent/CA2918105C/en active Active
- 2014-08-07 JP JP2016534614A patent/JP6746495B2/ja active Active
- 2014-08-07 PT PT14835826T patent/PT3033101T/pt unknown
- 2014-08-07 BR BR112016002401A patent/BR112016002401A8/pt not_active Application Discontinuation
- 2014-08-07 PL PL14835826T patent/PL3033101T3/pl unknown
- 2014-08-07 KR KR1020167006559A patent/KR102390714B1/ko active IP Right Grant
- 2014-08-07 WO PCT/US2014/050080 patent/WO2015023504A1/en active Application Filing
- 2014-08-07 SI SI201431109T patent/SI3033101T1/sl unknown
-
2016
- 2016-08-16 HK HK16109784.3A patent/HK1221644A1/zh unknown
- 2016-09-02 US US15/255,508 patent/US20170198049A1/en not_active Abandoned
- 2016-12-01 HK HK16113684A patent/HK1225302B/zh unknown
-
2019
- 2019-03-01 HR HRP20190405TT patent/HRP20190405T1/hr unknown
- 2019-03-12 CY CY20191100294T patent/CY1122132T1/el unknown
-
2020
- 2020-02-24 AU AU2020201327A patent/AU2020201327A1/en not_active Abandoned
- 2020-04-03 JP JP2020067797A patent/JP2020128375A/ja not_active Withdrawn
-
2022
- 2022-06-07 JP JP2022092216A patent/JP2022120009A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108991A patent/JP2024129139A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
BR112017022772A2 (pt) | métodos para tratar ou prevenir cefaleia de enxaqueca | |
CL2015000352A1 (es) | Métodos de tratamiento de una tauopatía | |
MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
AR081750A1 (es) | Anticuerpos anti-cd40 | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
PH12016500275A1 (en) | Antibodies | |
PH12016500753B1 (en) | Antibodies specific to fcrn | |
SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
BR112016010336A2 (pt) | Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer | |
BR112019011461A2 (pt) | terapia celular à base de nk melhorada | |
BR112017002729A2 (pt) | terapia de combinação para uso em um método para tratar um tumor sólido em um indivíduo, anticorpo, uso, composição farmacêutica, kit para tratar um tumor sólido, e, método para tratar um tumor sólido em um indivíduo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ASTRAZENECA AB (SE) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ASTRAZENECA AB (SE) |
|
B25A | Requested transfer of rights approved |
Owner name: ASTRAZENECA AB (SE) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |